Navigation Links
Medivation Announces Second Quarter 2009 Financial Results Teleconference and Webcast on August 5, 2009
Date:7/29/2009

SAN FRANCISCO, July 29 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss second quarter 2009 financial results and provide a general business update on Wednesday, August 5, 2009, at 4:30 p.m. Eastern Time. A press release for the second quarter ended June 30, 2009 will be released after markets close on August 5, 2009.

Interested parties may call 888-287-5532 from the U.S. or +1-719-325-2124 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, the Company is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer's medications in patients with mild, moderate and severe Alzheimer's disease. Further development of dimebon in patients with Huntington disease is also planned. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing, and a Phase 3 trial is expected to begin this year. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medivation to Present at 8th Annual Needham Life Sciences Conference
2. Medivation Announces Offering of 2,750,000 Shares of Common Stock
3. Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
4. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
5. Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update
6. Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
7. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
8. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
9. Medivation Announces Participation in Upcoming Conferences
10. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
11. Medivation Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Church, VA (PRWEB) , ... February 12, 2016 ... ... Store?, Feb. 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... issue in the life cycle of pharmaceutical products, garnering increased attention from all ...
(Date:2/12/2016)... ... 12, 2016 , ... The ThedaCare Center for Healthcare Value ... on April 5-7. The series is a multi-day, multi-workshop event designed to teach ... a broad range of topics, including coaching skills, the scientific method of problem ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Jones Agency, a ... across eastern Texas, is launching a cooperative charity drive with the Tarrant Area Food ... more than 50,000 individuals and families in need, the Tarrant County Food Bank offers ...
(Date:2/12/2016)... FLA (PRWEB) , ... February 12, 2016 , ... Miami ... dental implants to their Miami dental office. Beginning in January, Miami Dental Specialists ... titanium. Miami Dental Specialists are the first office to be chosen by the dental ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information ... Health Plans and PBMs,” an upcoming Feb. 24 webinar that will discuss ways ... big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Stem cells are primitive cells found in all multi-cellular ... to differentiate into mature cell types Stem cells are ... embryonic stem cells were derived from embryos in 1981, ... culturing of embryonic stem cells from non-human primates occurred ... As a result of these discoveries, stem cells can ...
(Date:2/11/2016)... , Feb. 11, 2016  Walgreens has committed to ... states and Washington, D.C. as part ... that was commended by shareholder advocacy organization As You Sow. ... You Sow. "Many people hold on to unneeded drugs because ... have tragic consequences." --> Conrad MacKerron , ...
(Date:2/11/2016)...  NOIT™ Research LLC, a private, leading-edge autism research ... to assist needy families in obtaining one of its ... February 10, 2016 and March 31, 2016, the company ... NOIT is an auditory stimulus that plays a key ... Beth Shier , NOIT Research director. ...
Breaking Medicine Technology: